Mylan gets green light to challenge Neurim melatonin patent
25-01-2022
Mylan gets Fed Circ reprieve in inhaler dispute
09-12-2021
Mylan scores multiple sclerosis patent win over Biogen
23-06-2020
ricochet64 / Shutterstock.com
The US Supreme Court has rejected a bid from generic drugmaker Mylan (now part of Viatris) to overturn the NHK-Fintiv rule.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Mylan, Viatris, Apple, USPTO, PTAB, Andrei Iancu, generics
